Advancement of clinical research using the company’s own cells
First written in FY2021. 9 of 12 entries say "Advanced", first in FY2022. Latest entry: FY2026.
1 other company's latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「In joint research with 株式会社iPSポータル on a manufacturing and storage service for autologous iPS cells derived from umbilical cord blood, we confirmed that high-quality iPS cells could be produced from cord blood that we had cryopreserved for more than 20 years, demonstrating that stored cord blood is an excellent source. The results were presented at a regenerative medicine conference held in March 2026.」
It was reported that high-quality iPS cells were produced from the company's own cord blood stored for more than 20 years, and that the research had progressed to a conference presentation. - FY2026-H1AdvancedAnnual report
「The clinical study received many applications to participate, exceeding the recruitment capacity, and administration has already been performed in the first case.」
The ASD clinical study using autologous cord blood nucleated cells, centered on Osaka Metropolitan University, progressed through subject recruitment to administration in the first case. - FY2025AdvancedAnnual report
「Clinical research on "developing a treatment using autologous cord blood nucleated cells for autism spectrum disorder (ASD)" has begun. ASD is said to be diagnosed in 1 in 100 people, and many people applied to participate when recruitment began for this clinical study. The first administration slot has already closed.」
The clinical study of autologous cord blood for autism spectrum disorder began and progressed through subject recruitment to the closing of the first administration slot. - FY2025-H1AdvancedAnnual report
「Clinical research on "developing a treatment using autologous cord blood nucleated cells for autism spectrum disorder," announced last June with the Department of Developmental Pediatrics at the Osaka Metropolitan University Graduate School of Medicine, has begun, and the company issued a press release on 29 October. Recruitment of participants (subjects) is scheduled to begin.」
Clinical research for autism spectrum disorder using autologous cord blood nucleated cells has begun and progressed to the stage of preparing to recruit participants. - FY2024-Q3RestatedAnnual report
「In Japan, the clinical study for children with cerebral palsy at the Department of Pediatrics of Kochi University Hospital is progressing smoothly. A group centered on the Department of Developmental Pediatrics at the Osaka Metropolitan University Graduate School of Medicine also continues to conduct clinical research for children with hypoxic-ischemic encephalopathy (HIE).」
The company reported the continuation of clinical research for pediatric neurological diseases using cord blood, centered on Kochi University and Osaka Metropolitan University. No new case numbers or trial-stage milestones are indicated. - FY2024-Q2AdvancedAnnual report
「The company announced in June this year that it had decided, together with the group, to begin "developing a treatment using autologous cord blood nucleated cells for autism spectrum disorder," and is preparing to begin clinical research in 2024.」
The development of a treatment for autism spectrum disorder using autologous cord blood nucleated cells has progressed to the preparation stage for clinical research to begin in 2024. - FY2024-Q1AdvancedAnnual report
「The company announced in June this year that it had decided, together with the group, to begin "developing a treatment using autologous cord blood nucleated cells for autism spectrum disorder."」
For the development of a treatment for autism spectrum disorder using autologous cord blood nucleated cells, a new research and development milestone was indicated: the decision to begin the program and its public announcement. - FY2023AdvancedAnnual report
「The results were published in a paper in November 2022.」
Publication of a paper was indicated as specific progress in the Phase I clinical study using autologous cord blood for pediatric cerebral palsy and other conditions conducted at Kochi University Hospital. - FY2023-Q2AdvancedAnnual report
「In August this year, the Department of Pediatrics at Kochi University Hospital published favorable results from Japan's first Phase I clinical study of autologous cord blood administration for children with cerebral palsy.」
Specific progress was reported in the form of publication of favorable results from Japan's first Phase I clinical study of autologous cord blood administration for children with cerebral palsy. Completion of administration to the first case was also indicated in the Phase II trial for children with HIE. - FY2023-Q1RestatedAnnual report
「In research and development in regenerative medicine, clinical research using cord blood for pediatric neurological diseases is under way in Japan at Kochi University Hospital, Osaka Metropolitan University Hospital and other institutions.」
The company reported that clinical research for pediatric neurological diseases using cord blood is continuing at Kochi University, Osaka Metropolitan University Hospital and other institutions. No new case numbers or clinical-stage milestones are indicated. - FY2022AdvancedAnnual report
「Patients were followed for approximately 3 years after the final administration, and follow-up was completed in May 2021. As of March 2022, the paper was under peer review and is expected to be published in the future.」
In Kochi University's Phase I clinical study using autologous cord blood, follow-up after the final administration in the 6th case was completed in May 2021, and the paper entered peer review. - FY2021First statedAnnual report
「With support from AMED (Japan Agency for Medical Research and Development), a group centered on the Osaka City University School of Medicine is conducting "autologous cord blood stem cell therapy for hypoxic-ischemic encephalopathy (HIE)." The Phase I clinical study, involving 6 cases, has already been completed, and the Phase II multicenter clinical study was published on jRCT dated 12 November 2020 and has commenced. Of the 15 planned cases in this clinical study, the company will be responsible for cell processing, including cord blood cell separation and transport, in 10 cases.」
The research status is described as 6 Phase I cases completed, with the company responsible for 10 of the 15 planned Phase II cases.